Stay updated on JCAR014 and Durvalumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.

Latest updates to the JCAR014 and Durvalumab in Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedThe study record view displays a 403 Forbidden message instead of trial details, with a link back to Home.SummaryDifference0.5%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a minimal error page and a Home link; a site revision note (Revision: v3.7.0) is shown, and large blocks of previously visible study data are removed.SummaryDifference29%

- Check36 days agoChange DetectedThe page revision tag was updated to v3.6.6 from v3.6.5, indicating a new version of the page documentation. This is a metadata update and does not alter the study content or user-facing information.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page revision tag was updated from Revision: v3.6.4 to Revision: v3.6.5, indicating a deployment with minor updates or fixes to the page's metadata. This change does not affect the visible content or primary functionality of the study page.SummaryDifference0.0%

- Check72 days agoChange DetectedThe study protocol documentation on the page updated its revision tag to v3.6.4, replacing the previous v3.6.3, indicating a newer version of the documented materials is now referenced.SummaryDifference0.0%

- Check93 days agoChange DetectedThe page revision was updated from v3.6.2 to v3.6.3, indicating a small update to the page's metadata/template. No study content, eligibility criteria, or results are impacted.SummaryDifference0.0%

Stay in the know with updates to JCAR014 and Durvalumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.